Artiria Medical raises CHF 3.8 million to improve stroke treatments
12.04.2022
Artiria Medical, a neurovascular EPFL spin-off startup, raised CHF 3.8 million, including a CHF 2.7 million grant from the highly selective EIC accelerator program and a CHF 1.1 million bridge financing.
 |
 |
With its breakthrough technology, Artiria has been awarded the highly selective EIC Accelerator Grant supporting disruptive innovation across Europe, funded by the Swiss State Secretariat for Education, Research and Innovation (SERI). Together with this grant, a CHF 1.1 M bridge financing has been secured with Artiria's current investors to further accelerate the deployment of its technology.
“We are thrilled to receive such a substantial grant from an extremely competitive program, probably one of the most challenging in Europe. This fantastic result would not have been possible without the strong commitment of our exceptional team.” said Guillaume Petit-Pierre, co-founder and Artiria’s CEO. With this additional CHF 3.8 million, Artiria will significantly advance the clinical and regulatory deployment of its first product. Artiria developed a revolutionary neurovascular guiding system intended for the treatment of diseases such as stroke. “We would like to thank our current investors for their contribution to this bridge financing round. Their constant support strongly contributes to accelerating our mission to bring disruptive innovations to the patients affected by stroke.” commented Marc Boers, co-founder and COO of Artiria.
Globally, one in four people over age 25 will have a stroke in their lifetime. This disease most often leads to severe disabilities and death. Currently, the standard of care is based on a minimally invasive approach, using the patient's arteries as an access route to reach the lesion and locally deliver life-saving treatments. However, this procedure can be very challenging, as the device navigation takes place in a dense network of tiny brain arteries. This complexity causes surgeons to lose significant and critical time before they can effectively deliver the therapy. Artiria’s technology addresses this medical need with an elegant and innovative solution particularly well integrated into current clinical practice.
Guillaume, you won Venture Kick in 2019. How did it help you lay the foundation for your growth and today's achievement?
Venture Kick has been a solid program that significantly accelerated our development and helped us to fine-tune our business case. This program was perfect to prepare Artiria for its first financing round!
You also participated in Venture Leaders Life Science in 2018 and were selected among the TOP 100 Swiss Startup Award in 2020 and 2021. How did it leverage your fundraising strategy?
Venture Leaders was a great experience. It brings you significant training to pitch your project plus it increases your investor's network significantly, which is great when you are raising funds. Being elected at the TOP 100 Swiss Startup Award is definitely a great recognition of the ecosystem and gave us good visibility to investors.
“We are thrilled to receive such a substantial grant from an extremely competitive program, probably one of the most challenging in Europe. This fantastic result would not have been possible without the strong commitment of our exceptional team.” said Guillaume Petit-Pierre, co-founder and Artiria’s CEO. With this additional CHF 3.8 million, Artiria will significantly advance the clinical and regulatory deployment of its first product. Artiria developed a revolutionary neurovascular guiding system intended for the treatment of diseases such as stroke. “We would like to thank our current investors for their contribution to this bridge financing round. Their constant support strongly contributes to accelerating our mission to bring disruptive innovations to the patients affected by stroke.” commented Marc Boers, co-founder and COO of Artiria.Globally, one in four people over age 25 will have a stroke in their lifetime. This disease most often leads to severe disabilities and death. Currently, the standard of care is based on a minimally invasive approach, using the patient's arteries as an access route to reach the lesion and locally deliver life-saving treatments. However, this procedure can be very challenging, as the device navigation takes place in a dense network of tiny brain arteries. This complexity causes surgeons to lose significant and critical time before they can effectively deliver the therapy. Artiria’s technology addresses this medical need with an elegant and innovative solution particularly well integrated into current clinical practice.
Guillaume, you won Venture Kick in 2019. How did it help you lay the foundation for your growth and today's achievement?Venture Kick has been a solid program that significantly accelerated our development and helped us to fine-tune our business case. This program was perfect to prepare Artiria for its first financing round!
You also participated in Venture Leaders Life Science in 2018 and were selected among the TOP 100 Swiss Startup Award in 2020 and 2021. How did it leverage your fundraising strategy?
Venture Leaders was a great experience. It brings you significant training to pitch your project plus it increases your investor's network significantly, which is great when you are raising funds. Being elected at the TOP 100 Swiss Startup Award is definitely a great recognition of the ecosystem and gave us good visibility to investors.